Invention Grant
- Patent Title: Inhibitors of the menin-MLL interaction
-
Application No.: US16308739Application Date: 2017-06-08
-
Publication No.: US10683302B2Publication Date: 2020-06-16
- Inventor: Salvacion Cacatian , David A. Claremon , Lawrence Wayne Dillard , Chengguo Dong , Yi Fan , Lanqi Jia , Stephen D. Lotesta , Andrew Marcus , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Jing Yuan , Yajun Zheng , Linghang Zhuang , Stephan D. Parent , Travis L. Houston
- Applicant: VITAE PHARMACEUTICALS, LLC
- Applicant Address: US NJ Madison
- Assignee: VITAE PHARMACEUTICALS, LLC
- Current Assignee: VITAE PHARMACEUTICALS, LLC
- Current Assignee Address: US NJ Madison
- Agency: Cooley LLP
- Agent Heidi A. Erlacher; Eric A. Owens
- International Application: PCT/US2017/036506 WO 20170608
- International Announcement: WO2017/214367 WO 20171214
- Main IPC: C07D405/14
- IPC: C07D405/14 ; C07D403/04 ; C07D403/14 ; C07D471/10 ; C07D487/10 ; C07D491/10 ; A61P35/02 ; C07D491/107 ; C07F9/6561
Abstract:
The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
Public/Granted literature
- US20190144459A1 INHIBITORS OF THE MENIN-MLL INTERACTION Public/Granted day:2019-05-16
Information query
